OXFORD BIOMEDICA
PLC
Oxford BioMedica Appoints Ex-Fisons And SmithKline Director
To The Board
Oxford
BioMedica announces today the appointment of Dr Peter Johnson
to its Board as a Non-Executive Director.
Dr Johnson
(BSc, PhD, FRSC, FIBiol, FRCPath), aged 63, has extensive
drug research and development experience with Wellcome,
Hoechst and Astra. He was formerly Chairman and Managing
Director of Smith Kline and French Research Limited and
Director of Pharmaceutical Research and Development and
Group Main Board Director of Fisons Plc. He is currently
a member of the board of Quadrant Healthcare Plc and chairman
of CBAMS Limited.
Prof.
Alan Kingsman, Chief Executive of Oxford BioMedica commented
"I am extremely pleased to welcome Peter Johnson to the
Board of Oxford BioMedica. As we progress with the development
of MetXia-P450TM, our first candidate product,
and continue to expand the pipeline of products in clinical
development, Peter's experience will be invaluable to our
future plans."
Peter
Johnson commented "I look forward to working with the BioMedica
team at an exciting stage in the Company's development.
In the past 2 years its progress in taking candidate products
to the clinic has been impressive. The promise of gene therapy
bringing revolutionary new treatments to a broad range of
medical applications appears now to be closer than ever
before. It is a pleasure to be joining a Company with such
a depth of innovative and unique technology at the forefront
of this exciting sector."
|
Notes
to Editors
1.
Oxford BioMedica: Established in 1995, the Company
specialises in the development and application of gene-based
therapeutics using advanced gene delivery technologies
for the treatment of disease in the areas of oncology,
viral infection, neurobiology, cardiovascular disease
and genetic deficiency. Oxford BioMedica plc was floated
on the UK Alternative Investment Market of the London
Stock Exchange in December 1996.
|
|
